Palbociclib Intermediate CAS 1016636-76-2 Ịdị Ọcha>99.0% (HPLC) Foto egosipụtara

Palbociclib Intermediate CAS 1016636-76-2 Dị Ọcha> Ụlọ ọrụ 99.0% (HPLC)

Nkọwa dị mkpirikpi:

Aha Chemical: 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one

Nọmba: 1016636-76-2

Dị ọcha:> 99.0% (HPLC)

Ọdịdị: White na Light Yellow Powder

Ọkara nke Palbociclib (CAS: 571190-30-2)

Ogo dị elu, mmepụta azụmahịa

E-Mail: alvin@ruifuchem.com

Zitere anyị email

Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Ruifu Chemical Supply Palbociclib metụtara Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H) -otu CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-otu CAS 1013916-37-4

Njirimara kemịkalụ:

Aha Chemical	6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H) -otu
Ụdị okwu	Palbociclib-Pb3
Nọmba CAS	1016636-76-2
Nọmba CAT	RF-PI1849
Ọnọdụ Ahịa	N'ọkwa, Mpụta Ihe ruru Tọn
Usoro ihe omimi	C13H13BrClN3O
Ibu molekụla	342.63
Ụdị	Ruifu Chemical

Nkọwapụta:

Ihe	Nkọwapụta
Ọdịdị	Ọcha na-acha odo odo ntụ ntụ
Ụzọ ịdị ọcha / nyocha	> 99.0% (HPLC)
Ihe ndị emetụtara	<1.00%
Ọnwụ na ihicha	<0.50%
Mmiri (KF)	<0.50%
Nlele ọkọlọtọ	Standardkpụrụ ụlọ ọrụ
Ojiji	Ọkara nke Palbociclib (CAS: 571190-30-2)

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri

Uru:

Ajụjụ:

Ngwa:

6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d] pyrimidin-7 (8H) -otu (CAS: 1016636-76-2) bụ etiti nke Palbociclib (CAS: 571190- 30-2).Palbociclib bụ ọgwụ maka ọgwụgwọ ER-positive na HER2-adịghị mma cancer ara mepụtara.Palbociclib bụ onye na-egbochi nhọrọ nke kinase nke dabere na cyclin CDK4 na CDK6.Na February 3, 2015, US FDA kwadoro Pfizer's Palbociclib (aha ahia: Ibrance) maka ọgwụgwọ nke ọrịa ara ara dị elu / metastatic na ụmụ nwanyị postmenopausal.Palbociclib bụ onye na-egbochi CDK4/6 mbụ nwetara nkwado FDA.